Oric Pharmaceuticals
ORIC
76 hedge funds and large institutions have $1.1B invested in Oric Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 41 increasing their positions, 7 reducing their positions, and 3 closing their positions.
767% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 3
486% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 7
100% more capital invested
Capital invested by funds: $553M → $1.1B (+$551M)
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
41% more funds holding
Funds holding: 54 → 76 (+22)
16.94% more ownership
Funds ownership: 73.94% → 90.88% (+17%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$31.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$27.5M |
| 3 |
Alkeon Capital Management
New York
|
+$17.1M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$16.8M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$12.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SG Americas Securities
New York
|
-$2.3M |
| 2 |
AG
Artal Group
Luxembourg
|
-$1.22M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$768K |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$269K |
| 5 |
MFS
Mirabella Financial Services
London,
United Kingdom
|
-$233K |
ORIC Hedge Fund Activity: Q4 2020 in Review
76 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q4 2020, worth a combined $1.1B — up 100% from $553M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ORIC positions and 3 closed out — a net gain of 23 holders — while 41 added to existing stakes and 7 trimmed.
The largest buyer was BlackRock, adding an estimated $31.7M. The largest seller was SG Americas Securities, exiting entirely with an estimated $2.3M sold.
- 76 institutional investors held Oric Pharmaceuticals (ORIC) as of Q4 2020, up from 54 in Q3 2020.
- Funds reported $1.1B of Oric Pharmaceuticals stock for Q4 2020, up 100% quarter-over-quarter.
- 26 funds opened new Oric Pharmaceuticals positions in Q4 2020 and 3 closed out, a net change of +23 holders.
- The largest Oric Pharmaceuticals buyer in Q4 2020 was BlackRock, an estimated $31.7M added.
- The largest Oric Pharmaceuticals seller in Q4 2020 was SG Americas Securities, an estimated $2.3M sold.
Based on aggregated 13F filings for Q4 2020.